诺华放射性疗法Pluvicto在华申报上市

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][7]. Core Insights - The pharmaceutical sector experienced a decline of 1.17% on November 13, 2024, underperforming the CSI 300 index by 1.79 percentage points, ranking 30th among 31 sub-industries [3]. - Notable performers within the pharmaceutical sub-industries included medical equipment (-0.13%), blood products (-0.37%), and vaccines (-0.41%), while offline pharmacies (-3.21%), hospitals (-2.34%), and medical research outsourcing (-2.27%) lagged behind [3]. - The top three gainers in individual stocks were Tuo Jing Life (+20.01%), Sai Li Medical (+10.06%), and Qidi Pharmaceuticals (+8.25%), whereas the largest decliners were Changyao Holdings (-10.32%), Lu Kang Pharmaceuticals (-8.91%), and Sihuan Bio (-8.19%) [3]. Summary by Sections Industry News - On November 13, 2024, Novartis' radioligand therapy Pluvicto received acceptance for its new drug application in China. This therapy targets PSMA and is linked to the radioactive isotope 177Lu, previously approved by the FDA in March 2022 for prostate cancer treatment [4]. - Several companies announced regulatory approvals for new drugs, including Sai Long Pharmaceuticals, Bu Chang Pharmaceuticals, and China Medical, indicating ongoing developments in the pharmaceutical sector [4].